Search

everythinglearnresearchcommunity

for

Search:↓

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

Rituximab may cause skin issues, but baricitinib can help improve them.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

Natural killer and CD8+ T cells play a key role in hair loss in androgenetic alopecia.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

The balance between cell renewal and differentiation controls the growth of cancerous cells in mouse skin.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.

Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.

IL-27 can prevent hair loss in alopecia areata.

Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.

Activating TLR3 helps improve skin and hair follicle regeneration after wounds.

Th22 cells are essential for Tβ15-induced hair growth in mice.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.